Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

Eli Lillys Zepbound has outperformed Novo Nordisks Wegovy in a recent clinical trial, with patients losing more weight on ...

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...

The connection between weight loss medications and addiction reduction represents a potentially transformative discovery in ...

Drugmaker Eli Lilly is claiming victory in the battle of weight loss drugs, now one of the most competitive and lucrative ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Dr. Matthew Knight, president of the Knight Dermatology Institute, explains how weight-loss drugs work and discusses whether ...

The Alliance for Pharmacy Compounding rebutted Novo's FDA petition to bar compounding pharmacies from copying its weight loss ...

People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...

A new study is out that compares the effectiveness of two popular weight loss drugs, Wegovy and Zepbound. The study, which ...

Engineers designed a new type of gastric balloon that can be inflated and deflated as needed. It could offer an alternative for people who don't want to undergo more invasive treatments such as ...